Search results
Adrian Blaser obtained his Masters and PhD in Chemistry from the University of Bern, Switzerland. After a postdoctoral position with Professor Margaret Brimble at the University of Auckland, Adrian was appointed as a Research Fellow in the Centre designing and developing novel drugs for cancer treatment.
View Adrian Blaser’s profile on LinkedIn, a professional community of 1 billion members. Senior Researcher at the University of Auckland; Honorary Consul at Consulate of Switzerland ·...
- 370
- The University of Auckland
- Gymnasium Bern
Adrian BLASER, Senior Researcher, NMR Manager | Cited by 1,037 | of University of Auckland, Auckland | Read 34 publications | Contact Adrian BLASER
I am now in charge of the NMR facility and look after the Analytical services in general at the ACSRC. View the University of Auckland profile of Adrian Blaser.
Sep 22, 2017 · It demonstrates excellent efficacy against TB but induces phospholipidosis at high doses, has a long terminal elimination half-life (due to its high lipophilicity), and exhibits potent hERG channel inhibition, resulting in clinical QTc interval prolongation.
- Amy S. T. Tong, Peter J. Choi, Adrian Blaser, Hamish S. Sutherland, Sophia K. Y. Tsang, Jerome Guill...
- 2017
Apr 1, 2019 · Abstract. The ATP-synthase inhibitor bedaquiline is effective against drug-resistant tuberculosis but is extremely lipophilic (clogP 7.25) with a very long plasma half-life.
Apr 1, 2019 · Abstract. Bedaquiline is a new drug of the diarylquinoline class that has proven to be clinically effective against drug-resistant tuberculosis, but has a cardiac liability (prolongation of the QT interval) due to its potent inhibition of the cardiac potassium channel protein hERG.
